An investigational anti-clotting medication, asundexian, has demonstrated a reduction in the risk of a second ischemic ...

An investigational anti-clotting medication, asundexian, demonstrated a reduction in the risk of a second ischemic ...

Eleven top scientists in stroke and brain health will be recognized for their individual exceptional professional achievements and contributions to stroke and brain health care and research during the ...

The factor XIa inhibitor asundexian reduced recurrent ischemic stroke without increasing major or minor bleeding in patients ...

In a phase III clinical trial in China, stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days starting within 48 hours of stroke symptoms, had a ...

For patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack, asundexian, a factor XIa inhibitor, reduced risk for secondary stroke with no excess risk for any bleeding vs ...

A new predictive tool may help identify patients at risk for poststroke dementia, potentially accelerating research and ...

The American Heart Association and American Stroke Association have issued an updated guideline for the diagnosis and treatment of acute ischemic stroke.The new guideline, published in Stroke, ...

Stroke patients face unequal access to clot-removal care; race and insurance shape transfers, even with Medicare—here’s what must change, according to Luke Messac, MD, PhD. Disparities in access to ...

Improving blood flow to the brain by opening a narrowed neck artery may not improve patients' cognitive skills, according to ...

In a phase III clinical trial in China, stroke patients treated intravenously with loberamisal, a novel neuroprotective ...